Suppr超能文献

马来西亚对新冠疫苗加强针的犹豫态度:一项基于网络的横断面研究。

COVID-19 Vaccine Booster Hesitancy in Malaysia: A Web-Based Cross-Sectional Study.

作者信息

Lee Kai Wei, Yap Sook Fan, Ong Hooi Tin, Oo Myo, Swe Kye Mon Min

机构信息

Department of Pre-Clinical Sciences, M. Kandiah Faculty of Medicine and Health Sciences, Universiti Tunku Abdul Rahman, Kajang 43000, Selangor, Malaysia.

Centre for Research on Communicable Diseases, Universiti Tunku Abdul Rahman, Kajang 43000, Selangor, Malaysia.

出版信息

Vaccines (Basel). 2023 Mar 13;11(3):638. doi: 10.3390/vaccines11030638.

Abstract

Vaccination is a key public health strategy that is known to be effective in mitigating the risk of infection and severe disease. However, in the context of the COVID-19 pandemic, the percentage (<50%) of Malaysians who have received a booster for the COVID-19 vaccine has remained stagnant over a year. This study aimed to determine the prevalence of and the factors associated with hesitancy toward the second dose of booster for the COVID-19 vaccine. A web-based cross-sectional study was conducted from August to November 2022. The Oxford Vaccine Hesitancy Scale was used to assess the hesitancy toward the second dose of booster for the COVID-19 vaccine. Simple and multiple factors logistic regressions were used to determine the predictors of hesitancy. A -value less than 0.05 was considered to be statistically significant. Data from 798 respondents were included in the analysis. The prevalence of hesitancy toward the second booster of the COVID-19 vaccine was 26.7%. The predictors of second-booster hesitancy were older age (AOR = 1.040, 95 CI = 1.022, 1.058), having received the third dose (first booster) because of instruction by the government (AOR = 2.125, 95% CI = 1.380, 3.274), concern about serious long term side effects of the vaccine (AOR = 4.010, 95% CI = 2.218, 7.250), and opinions of close friends and immediate family members that the booster is harmful (AOR = 2.201, 95% CI = 1.280, 3.785). Conversely, factors that appear to reduce vaccine booster hesitancy were acceptance of the third dose due to the high number of cases and the increasing rate of infection (AOR = 0.548, 95% CI = 0.317, 0.947), the belief that the vaccine will decrease the risk of getting the infection (AOR = 0.491, 95% CI = 0.277, 0.870), and opinions of close friends and immediate family members that the booster is helpful (AOR = 0.479, 95% CI = 0.273, 0.840). In conclusion, more than one-fifth of Malaysians were hesitant to take the second booster of the COVID-19 vaccine. This suggests that appropriate steps that increase vaccine acceptance, taking into consideration the findings of the present study, are needed to address this issue and to foster more positive attitudes toward vaccination. The survey was available in three main languages but limited to people with internet access; hence, it would likely be biased toward younger adults and social media users and exclude those with limited or no internet access, in particular older people. Therefore, the results are not representative of the Malaysian population at large and caution should be exercised when interpreting the findings.

摘要

疫苗接种是一项关键的公共卫生策略,已知在降低感染风险和严重疾病方面有效。然而,在新冠疫情背景下,马来西亚接种新冠疫苗加强针的人口比例(<50%)在一年多时间里一直停滞不前。本研究旨在确定对新冠疫苗第二剂加强针犹豫的发生率及其相关因素。2022年8月至11月开展了一项基于网络的横断面研究。采用牛津疫苗犹豫量表评估对新冠疫苗第二剂加强针的犹豫程度。使用单因素和多因素逻辑回归确定犹豫的预测因素。P值小于0.05被认为具有统计学意义。798名受访者的数据纳入分析。对新冠疫苗第二剂加强针犹豫的发生率为26.7%。第二剂加强针犹豫的预测因素包括年龄较大(调整后比值比[AOR]=1.040,95%置信区间[CI]=1.022,1.058)、因政府指令接种第三剂(第一剂加强针)(AOR=2.125,95%CI=1.380,3.274)、担心疫苗严重的长期副作用(AOR=4.010,95%CI=2.218,7.250)以及亲密朋友和直系家庭成员认为加强针有害(AOR=2.201,95%CI=1.280,3.785)。相反,似乎能降低疫苗加强针犹豫的因素包括因病例数多和感染率上升而接受第三剂(AOR=0.548,95%CI=0.317,0.947)、相信疫苗会降低感染风险(AOR=0.491,95%CI=0.277,0.870)以及亲密朋友和直系家庭成员认为加强针有帮助(AOR=0.479,95%CI=0.273,0.840)。总之,超过五分之一的马来西亚人对接种新冠疫苗第二剂加强针犹豫不决。这表明需要采取适当措施提高疫苗接受度,考虑到本研究结果,以解决这一问题并培养对疫苗接种更积极的态度。该调查提供三种主要语言,但仅限于有网络接入的人群;因此,可能偏向年轻成年人和社交媒体用户,排除了网络接入有限或无网络接入的人群,尤其是老年人。所以,结果并不代表全体马来西亚人口,在解读研究结果时应谨慎。

相似文献

本文引用的文献

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验